S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82

MEI Pharma Stock Forecast, Price & News

+0.92 (+37.55%)
(As of 11/30/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
26.82 million shs
Average Volume
763,170 shs
Market Capitalization
$379.87 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive MEIP News and Ratings via Email

Sign-up to receive the latest news and ratings for MEI Pharma and its competitors with MarketBeat's FREE daily newsletter.

MEI Pharma logo

About MEI Pharma

MEI Pharma, Inc. is a pharmaceutical company, which engages in the clinical development of therapies for cancer. Its drug candidates include Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, an oral PI3K delta inhibitor; Voruciclib, an oral CDK inhibitor; and ME-344, a mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.


MEI Pharma Sees Unusually High Options Volume (NASDAQ:MEIP)
November 30, 2021 |  americanbankingnews.com
MEI Pharma (NASDAQ:MEIP) Announces Quarterly Earnings Results
November 11, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Previous Symbol
Year Founded

Sales & Book Value

Annual Sales
$25.53 million
Book Value
$0.37 per share


Net Income
$-50.58 million
Net Margins
Pretax Margin




Free Float
Market Cap
$379.87 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.29 out of 5 stars

Medical Sector

280th out of 1,390 stocks

Pharmaceutical Preparations Industry

123rd out of 669 stocks

Analyst Opinion: 4.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

MEI Pharma (NASDAQ:MEIP) Frequently Asked Questions

Is MEI Pharma a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MEI Pharma stock.
View analyst ratings for MEI Pharma
or view top-rated stocks.

How has MEI Pharma's stock been impacted by Coronavirus?

MEI Pharma's stock was trading at $1.55 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MEIP shares have increased by 117.4% and is now trading at $3.37.
View which stocks have been most impacted by COVID-19

When is MEI Pharma's next earnings date?

MEI Pharma is scheduled to release its next quarterly earnings announcement on Thursday, February 3rd 2022.
View our earnings forecast for MEI Pharma

How were MEI Pharma's earnings last quarter?

MEI Pharma, Inc. (NASDAQ:MEIP) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13). The business had revenue of $13.39 million for the quarter, compared to the consensus estimate of $9.98 million. MEI Pharma had a negative net margin of 172.03% and a negative trailing twelve-month return on equity of 100.10%.
View MEI Pharma's earnings history

What price target have analysts set for MEIP?

5 brokers have issued 12-month price targets for MEI Pharma's shares. Their forecasts range from $8.00 to $20.00. On average, they expect MEI Pharma's stock price to reach $11.00 in the next year. This suggests a possible upside of 226.4% from the stock's current price.
View analysts' price targets for MEI Pharma
or view top-rated stocks among Wall Street analysts.

Who are MEI Pharma's key executives?

MEI Pharma's management team includes the following people:
  • Daniel P. Gold, President, Chief Executive Officer & Director
  • David M. Urso, Chief Operating Officer & General Counsel
  • Brian G. Drazba, Chief Financial Officer & Secretary
  • Richard G. Ghalie, Chief Medical Officer
  • Tina C. Beamon, Chief Compliance Officer

What other stocks do shareholders of MEI Pharma own?

What is MEI Pharma's stock symbol?

MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."

Who are MEI Pharma's major shareholders?

MEI Pharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.86%), Wasatch Advisors Inc. (5.63%), Geode Capital Management LLC (1.50%), Point72 Asset Management L.P. (0.97%), Renaissance Technologies LLC (0.89%) and Millennium Management LLC (0.43%). Company insiders that own MEI Pharma stock include Brian G Drazba, Daniel P Phd Gold, Frederick W Driscoll and Thomas C Reynolds.
View institutional ownership trends for MEI Pharma

Which institutional investors are selling MEI Pharma stock?

MEIP stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., BlackRock Inc., Goldman Sachs Group Inc., Two Sigma Advisers LP, Renaissance Technologies LLC, Millennium Management LLC, California State Teachers Retirement System, and Connor Clark & Lunn Investment Management Ltd..
View insider buying and selling activity for MEI Pharma
or view top insider-selling stocks.

Which institutional investors are buying MEI Pharma stock?

MEIP stock was bought by a variety of institutional investors in the last quarter, including Sigma Planning Corp, Bank of New York Mellon Corp, SG Americas Securities LLC, Geode Capital Management LLC, Barclays PLC, GSA Capital Partners LLP, BNP Paribas Arbitrage SA, and Man Group plc. Company insiders that have bought MEI Pharma stock in the last two years include Brian G Drazba, Daniel P Phd Gold, and Thomas C Reynolds.
View insider buying and selling activity for MEI Pharma
or or view top insider-buying stocks.

How do I buy shares of MEI Pharma?

Shares of MEIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MEI Pharma's stock price today?

One share of MEIP stock can currently be purchased for approximately $3.37.

How much money does MEI Pharma make?

MEI Pharma has a market capitalization of $379.87 million and generates $25.53 million in revenue each year. The company earns $-50.58 million in net income (profit) each year or ($0.66) on an earnings per share basis.

How many employees does MEI Pharma have?

MEI Pharma employs 51 workers across the globe.

What is MEI Pharma's official website?

The official website for MEI Pharma is www.meipharma.com.

Where are MEI Pharma's headquarters?

MEI Pharma is headquartered at 11455 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130.

How can I contact MEI Pharma?

MEI Pharma's mailing address is 11455 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The company can be reached via phone at (858) 369-7100, via email at [email protected], or via fax at 302-655-5049.

This page was last updated on 12/1/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.